Fig. 1.

Fisher’s exact test comparing the number of severe asthmatic patients treated for 12 months with benralizumab 30 mg Q8W or placebo achieving the clinical remission according to the four-item composite definition proposed by Menzies-Gow et al. [1] (zero exacerbations and zero OCS use and ACQ-6 ≤ 0.75 and pre-BD FEV₁ increase ≥ 100 mL). The analysis was performed on the overall population from SIROCCO [2] and CALIMA [3] studies (a) and in subgroup populations with blood eosinophil count ≥ 150 cells/μL (b) and ≥ 300 cells/μL (c). **P < 0.01 and ***P < 0.001. ACQ Asthma Control Questionnaire, BD bronchodilator, FEV₁ forced expiratory volume in 1 s, OCS oral corticosteroids, Q8W every 8 weeks, first three doses 4 weeks apart